Daily Sepsis Research Analysis
Analyzed 79 papers and selected 3 impactful papers.
Summary
Analyzed 79 papers and selected 3 impactful articles.
Selected Articles
1. Lipid mobilization establishes metabolic tolerance and prevents autonomic collapse in infection.
Across human sepsis data, murine models, and pharmacologic interventions, white adipose tissue lipolysis and circulating NEFAs were necessary and sufficient to promote metabolic tolerance and survival without altering pathogen burden. β3-adrenergic activation or exogenous fatty acid supplementation improved survival in mice, and propensity-matched real-world data linked β3-agonist exposure in septic patients to lower mortality/hospice discharge.
Impact: This work proposes a mechanistic tolerance pathway and a repurposing strategy using approved β3-agonists, potentially reframing sepsis therapy beyond pathogen eradication. The triangulation of human data, animal genetics, and pharmaco-epidemiology strengthens translational credibility.
Clinical Implications: If validated in RCTs, early β3-adrenergic support or targeted fatty acid supplementation could augment standard sepsis care by stabilizing autonomic function and improving survival. Monitoring and supporting metabolic tolerance may complement infection control and hemodynamic management.
Key Findings
- Higher circulating NEFAs in septic patients associated with reduced mortality.
- Adipose ATGL deletion impaired lipolysis, causing hypothermia, bradycardia, and increased mortality without altering pathogen burden.
- Restoring NEFAs, β3-adrenergic activation, or fatty acid supplementation rescued autonomic stability and improved survival in mice.
- Propensity-matched EHR analysis linked β3-agonist exposure to reduced mortality/hospice discharge among septic patients.
Methodological Strengths
- Triangulation across human observational data, genetic mouse models, and pharmacologic interventions.
- Rescue experiments (NEFA restoration) establishing necessity and sufficiency for tolerance.
Limitations
- Preprint status without peer review; key findings require independent replication.
- Observational EHR analyses are subject to residual confounding; clinical safety of β3-agonists in sepsis needs rigorous evaluation.
Future Directions: Biomarker-guided RCTs testing β3-agonists and/or tailored fatty acid support in sepsis; mechanistic dissection of tissue-specific lipid utilization and identification of patient subgroups benefiting from metabolic support.
UNLABELLED: Survival during infection depends on both pathogen clearance and the ability to tolerate infection-induced physiological changes. Metabolic adaptations are a central component of this tolerance, but the mechanisms underlying these responses remain incompletely defined. Here, we identify white adipose tissue (WAT) lipolysis as a central regulator of metabolic tolerance to infection. In patients with sepsis, higher circulating non-esterified fatty acid (NEFA) levels were associated with reduced mortality. In mouse models of polymicrobial sepsis, infection induced robust adipose lipolysis and increased circulating NEFAs. Genetic ablation of adipose triglyceride lipase (ATGL) in adipose tissue impaired lipolysis, leading to hypothermia, bradycardia, and increased mortality without altering immune cell populations or pathogen burden, consistent with a defect in tolerance rather than resistance. Mechanistically, lipolysis-derived NEFAs, but not glycerol, were required for protection, as restoring circulating NEFAs rescued autonomic stability and survival in adipose tissue ATGL-deficient mice.
2. NLRX1 alleviates sepsis-induced acute lung injury by activating mitophagy and suppressing NLRP3 inflammasome activation.
NLRX1 was downregulated in septic lungs and patient data, correlating with mitochondrial injury and NLRP3 activation. AAV9-mediated NLRX1 overexpression enhanced mitophagy via direct LC3B interaction, preserved mitochondrial function, reduced mtROS/mtDNA release, suppressed NLRP3 inflammasome activation and pyroptosis, and ameliorated lung injury and cytokinemia; these benefits were abolished by mitophagy inhibition.
Impact: Defines a mitochondria-centered immunometabolic mechanism linking NLRX1–LC3B interaction to mitigation of inflammatory lung injury, highlighting a druggable axis for septic ALI.
Clinical Implications: Therapeutic strategies that boost mitophagy or enhance NLRX1 signaling may reduce lung injury in sepsis; biomarkers of mitochondrial dysfunction could inform patient stratification.
Key Findings
- NLRX1 expression is decreased in sepsis and associates with mitochondrial damage and NLRP3 activation.
- AAV9-mediated NLRX1 overexpression promotes mitophagy via LC3B interaction, preserving mitochondrial membrane potential and ATP while reducing mtROS/mtDNA release.
- Enhanced mitophagy suppresses NLRP3 inflammasome activation and pyroptosis, reducing lung injury and systemic cytokines in CLP-induced sepsis.
- Mitophagy inhibition with Mdivi-1 abolishes the protective effects of NLRX1, confirming mechanism dependence.
Methodological Strengths
- In vivo AAV9 gene delivery with multimodal readouts (histology, TUNEL, TEM, cytokines) and in vitro validation.
- Mechanistic dissection with LC3B interaction and pharmacologic reversal using Mdivi-1.
Limitations
- Murine CLP and LPS-stimulated cell models may not fully recapitulate human septic ALI heterogeneity.
- AAV overexpression and Mdivi-1 have translational and off-target constraints; absence of human interventional validation.
Future Directions: Development of selective NLRX1 agonists or mitophagy enhancers; human translational studies linking mitochondrial biomarkers to outcomes and testing pathway-targeted therapies.
BACKGROUND: Sepsis-induced acute lung injury (ALI) is a life-threatening condition with limited therapeutic options. The mitochondrial protein NOD-like receptor X1 (NLRX1) has emerged as a potential immunometabolic modulator, but its functional role and mechanism in septic ALI remain poorly defined. METHODS: Bioinformatic analysis was performed on the GSE4607 sepsis dataset. A murine model of sepsis-induced ALI was established using cecal ligation and puncture (CLP), with NLRX1 overexpression achieved through adeno-associated virus serotype 9 (AAV9)-mediated gene delivery. Histopathological evaluation, TUNEL staining, and transmission electron microscopy, ELISA were employed to assess lung injury. Mouse lung epithelial cells (MLE-12) were stimulated with lipopolysaccharide (LPS), combined with NLRX1 overexpression and Mdivi-1-mediated mitophagy inhibition to explore the key mechanism by which NLRX1 improves ALI.
3. Clinical effects of glucagon-like peptide-1 receptor agonist in type 2 diabetes with low body mass index: findings from large-scale emulated target trials.
In matched cohorts of 20,928 per arm, GLP-1 RA initiation lowered risks of major adverse kidney events (HR 0.93) and dialysis (HR 0.78), and reduced hospitalization (HR 0.84) and sepsis (HR 0.88), with neutral cardiovascular and mortality effects. Benefits were consistent across BMI strata up to 30 kg/m² and clinical subgroups.
Impact: Demonstrates an association between GLP-1 RAs and reduced sepsis and hospitalization in non-obese T2D, extending potential benefits beyond glycemic and cardiovascular domains with large-scale, target trial–emulated evidence.
Clinical Implications: For T2D patients with BMI ≤30 kg/m², GLP-1 RAs may be favored when prioritizing kidney protection and reducing infections/hospitalization risk; however, causal effects require RCT confirmation.
Key Findings
- After 1:1 propensity matching (20,928 per group), GLP-1 RAs reduced MAKE (14.8% vs 16.8%; HR 0.93, p=0.005) and progression to dialysis (HR 0.78, p<0.001).
- Hospitalization (HR 0.84, p<0.001) and sepsis (HR 0.88, p=0.001) risks were lower with GLP-1 RAs.
- Cardiovascular outcomes and all-cause mortality were similar between GLP-1 RA and DPP-4i groups; effects consistent across BMI strata and subgroups.
Methodological Strengths
- Large real-world dataset with target trial emulation and rigorous 1:1 propensity score matching.
- Robustness across subgroup and sensitivity analyses with time-to-event methods.
Limitations
- Observational design with potential residual confounding and misclassification of outcomes (including sepsis).
- Neutral cardiovascular and mortality effects temper broad generalization; not a randomized head-to-head RCT.
Future Directions: Prospective randomized comparisons of GLP-1 RAs versus alternatives assessing infection-related outcomes; mechanistic studies of GLP-1–mediated infection risk reduction.
AIMS: Chronic kidney disease (CKD) is a common and serious complication of type 2 diabetes, yet the effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in non-obese or mildly overweight individuals remains uncertain. This study evaluated renal, cardiovascular, and systemic outcomes associated with GLP-1 RA therapy in adults with type 2 diabetes and body mass index (BMI) ≤ 30 kg/m². MATERIALS AND METHODS: We conducted a real-world, target trial emulation, retrospective cohort study using the TriNetX US Collaborative Network. Adults with type 2 diabetes and BMI ≤30 kg/m² initiating GLP-1 RAs or dipeptidyl peptidase-4 inhibitors (DPP-4i) between 2016 and 2023 were identified. After exclusions, 23,103 GLP-1 RA and 44,156 DPP-4i users remained; 1:1 propensity score matching yielded two balanced cohorts of 20,928 patients. Outcomes-including major adverse kidney events (MAKE), progression to dialysis, cardiovascular events, hospitalization, and sepsis-were assessed over up to four years. Cox regression and Kaplan-Meier analyses estimated hazard ratios.